New insights into clinical response in schizophrenia: From dopamine D 2 receptor occupancy to patients' quality of life

American Journal of Psychiatry

Volumn 165, Issue 8, 2008, Pages 940-943

  Goff, Donald C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BIFEPRUNOX; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PARTIAL AGONIST;

AGITATION; CORPUS STRIATUM; DOPAMINE RECEPTOR BLOCKING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDITORIAL; FUNCTIONAL STATUS; HALF LIFE TIME; HUMAN; INSOMNIA; MENTAL PATIENT; NAUSEA; NEUROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; HUMANS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; QUINOLONES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 48949086466     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.08050673     Document Type: Editorial

References (12)

1. 18F]fallypride PET study. Am J Psychiatry 2008; 165:988-995
2. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RSE: Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008; 165:978-987
3. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S: Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007; 164:1411-1417
4. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136
5. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF: Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27:248-259
6. Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T: Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 2007; 574:103-111
7. Heinrichs DW, Hanlon TE, Carpenter WT: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-396
8. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330
9. Harvey PD, Velligan DI, Bellack AS: Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr Bull 2007; 33:1138-1148
10. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163:418-425
11. Lehman AF: Instruments for measuring quality of life in mental illnesses, in Quality of Life in Mental Disorders. Edited by Katschnig H, Freeman H, Sartorius N. New York, John Wiley & Sons, 1997, pp 79-94
12. Eack SM, Newhill CE: Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 2007; 33:1225-1237